Youd think only people that were trading for a quick buck on the news would be selling today.. the results arent bad but not as good as hoped. Not surprising given the stagnant SP, but safety was ticked off which is important for phase 2A.
The people that fail to understand the design of the trial will judge this purely on whether it was statistically significant or not.
Ann: Admedus Releases Results of HSV-2 Phase IIa Study, page-50
-
- There are more pages in this discussion • 301 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add AVR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$12.49 |
Change
0.490(4.08%) |
Mkt cap ! $264.0M | |||
| Open | High | Low | Value | Volume |
| $12.11 | $12.49 | $11.50 | $155.8K | 13.16K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 175 | $11.81 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $12.49 | 77 | 1 |
View Market Depth
| Last trade - 16.10pm 27/09/2024 (20 minute delay) ? |
| AVR (ASX) Chart |